Pitt Street Research on Prescient Therapeutics

Stuart Roberts, co-founder and senior analyst at Pitt Street Research, outlined the recent Pitt Street Research report on Prescient Therapeutics.

Stuart discussed the key highlights, below:

  • Why Pitt Street believe Prescient stock may be seriously undervaluing a potential near-term payday with the PTX-100 treatment for T-Cell Lymphoma
  • How CellPryme and OmniCAR improve existing CAR-T technologies
  • Why Pitt Street sees Prescient re-rating as it continues to generate good clinical data from assets in the pipeline and move towards eventual commercialisation.

View Pitt Street Research

Recorded on 22nd November 2023 at 2pm (AEDT).

Featured Speakers

STUART ROBERTS

Co-Founder and Senior Analyst
Pitt Street Research

Stuart Roberts is an investment professional with many years experience in Australian equity research. Stuart covered healthcare and biotechnology for the stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015 where he developed a reputation for detailed analysis on previously uncovered Life Science companies.

Throughout his career, Stuart has held roles at Prima Biomed (NASDAQ: PBMD), a cancer immunotherapy biotech company, and cancer immunotherapy company, Imugene (ASX: IMU). Stuart co-founded Pitt Street Research in 2018 with the aim of providing issuer-sponsored equity research to the entire spectrum of ASX-listed companies.

Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics and may receive fees for its services.

Pitt Street Research Pty Ltd has been engaged and paid by the Prescient Therapeutics for ongoing research coverage.

Any advice contained within this presentation is general advice and does not consider your personal circumstances, you should consider whether it is appropriate for you. The information we are giving you is for educational purposes only. “Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss.

Past performance is not a reliable indicator of future performance.

This update is being hosted by Reach Markets Pty Ltd (CAR of AFSL 333297) and Reach does not assume responsibility for the accuracy or completeness of any information provided, and any communication from Reach has been prepared with all reasonable care and may be based on unverified information obtained from sources believed to be reliable. However, except to the extent required by law, Reach including its representatives, employees, agents or contractors are not liable to you for any loss or damage resulting directly or indirectly from access to information and do not accept any responsibility for errors and omissions, nor make any warranty or representation as to the reliability, suitability, confidentiality, accuracy, completeness or timeliness of information as it may change without notice and so Reach has no obligation to keep the information current.

Forward Looking Statements relate to intentions, future acts and events that are only predictions and are subject to risks, uncertainties and assumptions, which are outside the control of Reach. These may include commodity prices, currency fluctuations, economic and financial market conditions in various countries and regions, environmental risks and legislative, fiscal or regulatory developments, political risks, project delay or advancement, approvals and cost estimates. Actual values, results or events may be materially different to those expressed or implied and given these uncertainties, readers are cautioned not to place reliance on Forward Looking Statements. Information and views from third parties may be produced solely for convenience and are not endorsed nor reflective of Reach’s position.

latest other webcasts

Pitt Street Research on Prescient Therapeutics

Felix Gold Limited Investor Briefing Replay- 15th September

EBR Systems Inc Investor Briefing – 23 August